Interventional Glaucoma

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

A singular celebration of science over the decades

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

Priorities can ensure optimal outcomes for patients diagnosed with diseases.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

Mark J. Gallardo, MD, highlighted the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension.

The investigators conducted a multicenter, prospective, open-label, phase 4 study in which they evaluated the patients’ and investigators’ impressions of the drug.

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.

The audiobook of GRF's flagship 40-page educational booklet "Understanding and Living with Glaucoma is narrated by Bianca Beach, an actress, advocate, and glaucoma patient.

Results from the trial by Nannodropper show microdrops could reduce waste, cost, and side effects while being as effective as traditional size drops.

According to the company, NCX 470 is a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

According to the foundation, the grants were awarded to 18 investigators at prominent universities in the United States, Nigeria, and Hong Kong.

Neda Shamie, MD, previews a collaborative day packed with guest speakers, discussions on advanced patient care, and hands-on labs.

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.

Study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

Andrew G. Iwach, MD, recounts two personal life experiences that underscore the significance of patient-centered care in glaucoma management.

During the 2024 American Glaucoma Society meeting held February 29 to March 3 in Huntington Beach, California, Nixoc SA presented posters outlining data on NCX 470.

David Sola-Del Valle, MD, sat down with David Hutton of Ophthalmology Times to discuss his talk at the annual American Glaucoma Society meeting held in Huntington Beach, about the importance of bridging the language barrier in patients who may not be fluent in English.

April Maa, MD, sat down with David Hutton of Ophthalmology Times to discuss her presentation at the annual American Glaucoma Society meeting held in Huntington Beach, about tips and tricks for implementing telehealth into ophthalmology.

Repetitive exercises before drop instillation, may decrease difficulty and improve the successful instillation of eye drops.

Michael Greenwood, MD, discusses the safety of laser refractive surgery for patients at high risk for glaucoma, focusing on the need for thorough pre-surgery assessment, careful monitoring of eye pressure during and after the procedure, and awareness of prolonged steroid use following PRK.

Steven R. Sarkisian, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster about the Travoprost intraocular implant in phakic eyes from the American Glaucoma Society meeting held in Huntington Beach